ArticleThe EMBO journal2024
Early-stage lung cancer is driven by a transitional cell state dependent on a KRAS-ITGA3-SRC axis.
Abstract read
In one paragraph
Article in The EMBO journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- [Application and Progress of Organoid-on-a-chip Platforms in Lung Cancer Diagnosis and Therapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Pooled it
- Transitional cell states at the crossroads of development, disease, and repair-regeneration.Physiological reviews · 2026Review
- Article
- Article
- Article
- ITGA8 suppresses proliferation and metastasis of lung adenocarcinoma through the inhibition of glycolysis.Scientific reports · 2026Article
- Evolution of Cancer Metastases via Lineage Trans-Differentiation.Research (Washington, D.C.) · 2026Article
- Review
- Proteome-wide Mendelian randomization and colocalization analysis uncovers druggable targets for lung cancer across multiple phenotypes and complications.Discover oncology · 2025Article
- Persistent lineage plasticity driving lung cancer development and progression.Clinical and translational medicine · 2025Review
- Building blocks for lung regeneration: Stem cells and niches.Molecules and cells · 2025Review
- Oncogenic Mutations and the Tumor Microenvironment: Drivers of Non-Small Cell Lung Cancer Progression.Cancers · 2025Review
- Aging directs the differential evolution of KRAS-driven lung adenocarcinoma.bioRxiv : the preprint server for biology · 2025Article
- Bridging the gap: how patient-derived lung cancer organoids are transforming personalized medicine.Frontiers in cell and developmental biology · 2025Review
- S100A16 stabilizes the ITGA3‑mediated ECM‑receptor interaction pathway to drive the malignant properties of lung adenocarcinoma cells via binding MOV10.Molecular medicine reports · 2025Article
- Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.American journal of respiratory and critical care medicine · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Aaron L MoyeStem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA.
Antonella Fm DostStem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA.
Robert IetswaartDepartment of Genetics, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0001-9290-4741
Shreoshi SenguptaStem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA.
VanNashlee YaStem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA.
Chrystal AluyaStem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0009-0004-7157-253X
Caroline G FaheyStem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0003-4155-5662
Sharon M LouieStem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA.
Margherita PaschiniStem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA.
Carla F KimStem Cell Program and Divisions of Hematology/Oncology and Pulmonary Medicine, Boston Children's Hospital, Boston, MA, USA. carla.kim@childrens.harvard.edu.ORCID http://orcid.org/0000-0002-2366-9538
Funding
Project 3P50CA265826 · NCI · DANA-FARBER CANCER INST · PI David A Barbie · 2022 to 2026
$13.7MMicroenvironmental control of progenitors in organ dysfunction and repairU01HL100402 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI KIM, CARLA F., SCADDEN, DAVID T · 2009 to 2015
$8.5MCell-cell interactions governing lung epithelial progenitor cellsR35HL150876 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI Carla F. Kim · 2020 to 2026
$6.2MMechanisms of tumorigenesis in Brg1 mutant lung cancerR01CA216188 · NCI · BOSTON CHILDREN'S HOSPITAL · PI KIM, CARLA F., WONG, KWOK KIN · 2018 to 2022
$3.3MRole of METTL3 and the m6A Epitranscriptome in cancerR01CA233671 · NCI · BOSTON CHILDREN'S HOSPITAL · PI GREGORY, RICHARD I., KIM, CARLA F. · 2020 to 2024
$3.2MIn Vivo and In Vitro Characterization of Bronchio-Alveolar Stem CellsR01HL090136 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KIM, CARLA F. · 2007 to 2010
$1.9MSignaling pathways in lung stem cell differentiationR01HL125821 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KIM, CARLA F. · 2015 to 2018
$1.8MMechanisms of Thrombospondin-1 as a pulmonary vascular mediatorR01HL132266 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI KIM, CARLA F. · 2017 to 2020
$1.6MBurroughs Wellcome Fund (BWF) 1019903Cystic Fibrosis Foundation (CFF) KIM19P0Damon Runyon Cancer Research Foundation (DRCRF) DRG:2368-19European Molecular Biology Organization (EMBO) ALTF 2016-422HHS | National Institutes of Health (NIH) R01 HL090136,R01 HL132266,R01 HL125821,U01 HL100402,RFA-HL-09-004,R35HL150876NCI NIH HHS P50 CA265826NCI NIH HHS R01 CA216188NCI NIH HHS R01 CA233671NHLBI NIH HHS R01 HL090136NHLBI NIH HHS R01 HL125821NHLBI NIH HHS R01 HL132266NHLBI NIH HHS R35 HL150876NHLBI NIH HHS U01 HL100402
Abstract
Glycine-12 mutations in the GTPase KRAS (KRAS
Indexed as
Lung NeoplasmsOrganoidsProto-Oncogene Proteins p21(ras)Adenocarcinoma of LungAnimalsCell DifferentiationGene Expression Regulation, NeoplasticHumansIntegrin alpha3MiceMutationsrc-Family KinasesHras protein, mouseIntegrin alpha3ITGA3 protein, humanItga3 protein, mouseKRAS protein, humanProto-Oncogene Proteins p21(ras)src-Family KinasesAdenocarcinomaAT2Cell StatesKRASLung
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.